Statin‐induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database

Abstract

The present disproportionality analysis revealed a possible drug safety signal linking MG and statins. This potential signal is weak, and is offset by the cardiovascular benefits of statins. Clinicians should be aware of this potential ADR, because it may require consideration of statin withdrawal or treatment of MG.